Testing a new cancer drug alone and with other therapies
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of cancer that has spread or cannot be removed with surgery, and standard treatments have stopped working.
- You must provide a tumor sample from a previous biopsy or agree to a new biopsy if needed (unless you have glioblastoma).
- Your cancer must be measurable on scans (like CT or MRI).
- Your kidneys, liver, and blood counts must be working well enough, as determined by blood tests.
- You cannot have had cancer treatment (chemo, radiation, etc.) in the last 14 days, and any side effects from past treatments should be mild or gone.
- You cannot have serious heart problems, active infections, or a history of severe allergic reactions to antibody treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This early-stage trial tests a new experimental drug (MST-0312) in people with solid tumors like lung cancer, melanoma, bladder cancer, colorectal cancer, or triple-negative breast cancer. The goal is to find safe doses and see how well it works, either by itself or paired with other treatments.
This trial tests a new drug called N-3C01, alone or combined with immune-boosting medications, in patients whose advanced cancer has stopped responding to standard treatments. The goal is to see if this approach can slow or shrink tumors that have become resistant to other therapies.
This trial tests a new drug, M0324, alone or combined with pembrolizumab or chemotherapy, for advanced solid tumors that have a protein called MUC-1 on their surface. It may be an option for patients whose cancer has not responded to standard treatments.
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.